Opportunity Information: Apply for RFA HL 24 011
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center funding opportunity (RFA-HL-24-011) is an NIH cooperative agreement (U24) intended to strengthen and sustain the infrastructure needed to run complex, multi-site clinical research in hematopoietic cell transplantation (HCT) and related cell therapy (CT). The central goal is to move the field forward for all transplant-eligible patients, with a clear emphasis on populations that are especially hard to study and treat, such as patients with rare non-malignant blood disorders and patients with hematologic cancers where current approaches are limited or outcomes remain poor. In practical terms, NIH is supporting a coordinated network that can design and execute rigorous trials testing new transplant strategies, novel cellular therapies, and improvements in supportive care and long-term outcomes.
A key feature of the opportunity is the creation or continuation of a Data Coordinating Center (DCC) that serves as the operational and scientific backbone for the network. The DCC is expected to manage the core functions that make multi-center trials feasible and credible: protocol coordination, data management and quality control, regulatory and operational harmonization across sites, statistical design and analysis, trial monitoring, and efficient reporting to stakeholders. Alongside the DCC, NIH will support core clinical sites and a limited number of trials directly through funds requested under this initiative, while also anticipating that additional studies and trials will be brought into the network through partnerships. Those partnerships may include collaborations with R01-funded investigators, industry sponsors, and disease foundations, which helps expand the network research portfolio beyond what can be covered by the U24 award alone.
The announcement highlights why a longer performance period is necessary for transplantation and cell therapy research. HCT and CT trials often extend beyond the typical five-year window due to several built-in realities: eligible patient populations can be small (especially for rare diseases), which can stretch enrollment over multiple years; cell manufacturing and product logistics can be complex and time-consuming; and many of the outcomes that matter most in transplant medicine occur well after the procedure. The notice specifically points to composite and longer-horizon endpoints like disease-free survival and chronic graft-versus-host disease (GVHD)-free survival, which may not be fully observed until two or more years after transplant. Because of these constraints, NIH indicates that a seven-year program is needed to properly enroll participants, follow them long enough to capture meaningful endpoints, and complete analyses that can change clinical practice.
This opportunity is categorized under Education and Health and is associated with CFDA numbers 93.395 and 93.839. It is offered by the National Institutes of Health, with an original closing date of October 2, 2023, and a creation date of June 20, 2023. While the source text does not specify an award ceiling or the expected number of awards, the structure described makes clear that NIH is investing in sustained national coordination capacity rather than a short, single-project effort.
Eligibility is broad across U.S.-based organizations and government entities, reflecting the national scope of the network and the diverse institutions involved in transplant research and delivery. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as stated); for-profit organizations other than small businesses; small businesses; and other eligible entities. The announcement also explicitly calls out additional eligible institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
At the same time, the opportunity is restrictive with respect to foreign involvement. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. In other words, the applicant organization and the supported components must be domestic, which simplifies governance, compliance, and oversight for a U.S.-funded clinical trials network.
Finally, the title includes an important administrative boundary: "Clinical Trial Not Allowed." In NIH terms, that generally means the U24 mechanism itself is not intended to be used by the awardee to propose and independently conduct a clinical trial as the primary funded activity under the grant. Instead, the focus is on infrastructure and coordination for the network, with trial activities supported in a controlled and networked way as described in the announcement (including a limited number of trials and additional trials supported through collaborations). The overall intent is to ensure the field has the long-term coordinating capacity to run high-quality HCT and CT studies that are difficult to execute without centralized data, statistical, operational, and regulatory leadership.Apply for RFA HL 24 011
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "The Blood and Marrow Transplant Clinical Trials Network - Data Coordinating Center (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395, 93.839.
- This funding opportunity was created on 2023-06-20.
- Applicants must submit their applications by 2023-10-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the BMT CTN Data Coordinating Center funding opportunity (RFA-HL-24-011)?
RFA-HL-24-011 is an NIH cooperative agreement (U24) funding opportunity to create or continue the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center (DCC). The purpose is to strengthen and sustain the national infrastructure needed to run complex, multi-site clinical research in hematopoietic cell transplantation (HCT) and related cell therapy (CT).
What is the main goal of this opportunity?
The central goal is to move the HCT and CT field forward for all transplant-eligible patients, with a clear emphasis on patient populations that are especially hard to study and treat. Examples highlighted include patients with rare non-malignant blood disorders and patients with hematologic cancers where current approaches are limited or outcomes remain poor.
What is being funded: a clinical trial or coordinating infrastructure?
The focus is on infrastructure and coordination through a Data Coordinating Center (DCC). The opportunity title includes "Clinical Trial Not Allowed," which signals that the U24 award itself is not intended for the awardee to propose and independently conduct a clinical trial as the primary funded activity. Instead, the award supports the coordinating capacity that enables rigorous networked trials and studies to be designed and executed.
What does "Clinical Trial Not Allowed" mean in practical terms for this U24?
It means the primary activity under this U24 is not to run a stand-alone clinical trial initiated and conducted independently by the awardee as the main purpose of the award. The emphasis is on building and operating the network backbone (data, statistics, coordination, monitoring, and harmonization) that supports clinical research activity in a structured, networked way.
What is a Data Coordinating Center (DCC) in the context of BMT CTN?
The DCC is the operational and scientific backbone for a multi-site clinical trials network. It provides centralized coordination and technical leadership that make complex, multi-center trials feasible, consistent, and credible across participating sites.
What core functions is the DCC expected to perform?
Based on the opportunity description, the DCC is expected to manage core functions including protocol coordination, data management and quality control, regulatory and operational harmonization across sites, statistical design and analysis, trial monitoring, and efficient reporting to stakeholders.
What kinds of research does this network infrastructure support?
The network is intended to design and execute rigorous trials that test new transplant strategies, novel cellular therapies, and improvements in supportive care and long-term outcomes in HCT and related cell therapy.
Which patient populations are emphasized in the announcement?
The opportunity places a clear emphasis on populations that are difficult to study and treat, including patients with rare non-malignant blood disorders and patients with hematologic cancers where current approaches are limited or outcomes remain poor.
Why does NIH indicate a longer performance period is needed for HCT and CT trials?
HCT and CT trials often take longer than a typical five-year window because eligible patient populations can be small (especially for rare diseases), enrollment can take multiple years, cell manufacturing and product logistics can be complex, and many clinically meaningful outcomes occur well after the procedure.
How long is the program period described for this opportunity?
The notice indicates a seven-year program is needed to enroll participants, follow them long enough to capture meaningful endpoints, and complete analyses that can change clinical practice.
What longer-horizon endpoints are mentioned as examples of why follow-up takes time?
The announcement specifically points to composite and longer-horizon endpoints such as disease-free survival and chronic graft-versus-host disease (GVHD)-free survival, which may not be fully observed until two or more years after transplant.
Does NIH plan to support actual trials in addition to the DCC?
Yes. Alongside the DCC, NIH will support core clinical sites and a limited number of trials directly through funds requested under this initiative, while anticipating that additional studies and trials will be brought into the network through partnerships.
What kinds of partnerships are anticipated to expand the network's research portfolio?
The opportunity anticipates partnerships that may include collaborations with R01-funded investigators, industry sponsors, and disease foundations. These collaborations are intended to expand the network research portfolio beyond what can be covered by the U24 award alone.
Who is the sponsoring agency for this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What funding mechanism is being used?
This opportunity uses an NIH cooperative agreement mechanism, specifically U24.
What is the opportunity category?
The opportunity is categorized under Education and Health.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.395 and 93.839.
What are the key dates provided in the source information?
The creation date is June 20, 2023, and the original closing date is October 2, 2023.
Is the award ceiling or expected number of awards specified in the provided information?
No. The source text does not specify an award ceiling or the expected number of awards.
What does the structure of the opportunity suggest NIH is investing in?
The structure described suggests NIH is investing in sustained national coordination capacity for complex HCT and CT clinical research, rather than a short-term, single-project effort.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and government entities. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as stated); for-profit organizations other than small businesses; small businesses; and other eligible entities.
Are specific institution types explicitly named as eligible?
Yes. The announcement explicitly calls out Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). It also notes faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Are non-U.S. (foreign) entities allowed to apply?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply.
Can a U.S. organization apply if it plans to include non-domestic components?
No. The opportunity states that non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy definitions?
No. Foreign components, as defined by the NIH Grants Policy Statement, are not allowed for this opportunity.
What is the overall intent of funding a DCC for BMT CTN?
The overall intent is to ensure the field has long-term coordinating capacity to run high-quality HCT and CT studies that are difficult to execute without centralized data, statistical, operational, and regulatory leadership.
Browse more opportunities from the same category: Education, Health
Next opportunity: NIDA REI: Academic Research Enhancement Award (AREA) Training a Diverse Data Science Workforce for Addiction Research (R15 Clinical Trial Not Allowed)
Previous opportunity: NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 24 011
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 24 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional) Apply for RFA HL 24 010 Funding Number: RFA HL 24 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advancing Cancer Control Equity Research through Transformative Solutions Coordination Center (U24 Clinical Trial Optional) Apply for RFA CA 23 027 Funding Number: RFA CA 23 027 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Advancing Cancer Control Equity Research Through Transformative Solutions (U19 Clinical Trial Optional) Apply for RFA CA 23 026 Funding Number: RFA CA 23 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Limited Competition: NIH-DoD-VA Pain Management Collaboratory - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AT 24 002 Funding Number: RFA AT 24 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,300,000 |
| ADVANCE Predoctoral T32 Training Program to Promote Diversity in Health Disparities Research, Preventive Interventions, and Methodology (T32, Clinical Trial Not Allowed) Apply for RFA OD 23 018 Funding Number: RFA OD 23 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) Apply for PA 23 231 Funding Number: PA 23 231 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed) Apply for RFA CA 23 037 Funding Number: RFA CA 23 037 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 036 Funding Number: RFA CA 23 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $325,000 |
| NIH-DoD-VA Pain Management Collaboratory ? Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required) Apply for RFA AT 24 004 Funding Number: RFA AT 24 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 25 014 Funding Number: RFA DA 25 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) Apply for PAR 23 246 Funding Number: PAR 23 246 Agency: National Institutes of Health Category: Education, Health Funding Amount: $475,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional) Apply for RFA DA 25 020 Funding Number: RFA DA 25 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) Apply for RFA DA 25 019 Funding Number: RFA DA 25 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing HIV in highest risk sexual and gender minorities (R34 Clinical Trial Required) Apply for RFA DA 25 002 Funding Number: RFA DA 25 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Addressing HIV in Highest Risk Sexual and Gender Minorities (R01 Clinical Trial Optional) Apply for RFA DA 25 001 Funding Number: RFA DA 25 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) Apply for PAR 23 254 Funding Number: PAR 23 254 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) Apply for PAR 23 255 Funding Number: PAR 23 255 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) Apply for PAR 23 245 Funding Number: PAR 23 245 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) Apply for PAR 23 259 Funding Number: PAR 23 259 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 23 243 Funding Number: PAR 23 243 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 24 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.